Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and the lives of patients worldwide.
INNOVATIVE TOPICAL THERAPIES FOR MILLIONS OF PATIENTS WORLDWIDE
The Oculis strategy is to build a innovative ophthalmology company unlike any other. Our plan is to:
- Further advance our lead candidates: OCS-01 as a new therapeutic option for DME and post-cataract inflammation and OCS-02 for front-of-the-eye inflammation.
- Leverage our formulation discovery platforms (SNP technology and others) to develop a clinical pipeline of topical treatments for back and forth-of-the-eye diseases.
OCS-01 A POTENTIAL PARADIGM SHIFT IN DME TREATMENT
Our most advanced product candidate based on SNP technology is OCS-01, which recently completed two Phase 2 studies, one in DME and one in Pain and Inflammation following cataract surgery. The study in DME is the first proof-of-concept of a topical drug effect on a chronic retinal disease and is also a successful proof-of-concept for the SNP formulation technology. If approved in DME, it has the potential to provide a new option for patients whose current therapies are limited to intravitreal injections or implants. The study in post-cataract surgery is the first proof-of-concept of a once daily topical steroid for treating Inflammation and Pain following ocular surgery. OCS-01 is moving into phase III, following a positive End of Phase 2 meeting, in both indications.
TAKING TREATMENT FROM INJECTIONS TO DROPS FOR RETINAL DISEASES
Our novel formulation SNP technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.